Rodin Therapeutics, a Cambridge, MA-based biotechnology company applying insights from epigenetics to develop novel therapeutics for neurological disorders, raised $17.3m in funding.
Backers included Atlas Venture and Biogen. In addition to this financing, Rodin and Biogen have entered into a multi-year research collaboration around neuronal epigenetics. As part of the research collaboration between the two companies, Biogen will have the option to acquire Rodin at certain pre-defined milestones at pre-negotiated terms, including total upfront and milestone payments of up to $485m.
As part of the funding, Dr. Samantha Budd Haeberlein, Biogen VP of Clinical Development, will join Rodin’s Board of Directors.
Co-founded in 2013 by Atlas Venture and Proteros Biostructures and led by Adam Rosenberg, President and Chief Executive Officer, Rodin is discovering and developing therapeutics for cognitive disorders. The company has advanced its internal pipeline of epigenetic modulators and obtained an exclusive license to an additional chemical series discovered at the Broad Institute. Rodin’s drug candidates also have the potential to treat other conditions, including Parkinson’s disease, cognitive impairment in schizophrenia, and post-traumatic stress disorder.